Recent

% | $
Quotes you view appear here for quick access.

Itron, Inc. Message Board

alfred11111 634 posts  |  Last Activity: Jan 25, 2013 10:30 AM Member since: Jun 3, 2012
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Thank You For Applying!

    You've just finished an application for the following position:

    Job Title: Tax Manager or Senior Tax Manager
    Company: Sterling Search Group

    Your resume has been sent via email to the employer. You will receive an email confirmation once it is received by the employer.

    Start a new search



    Other jobs you might be interested in:

    Show only jobs with Quick Apply

    Sentiment: Strong Buy

  • alfred11111 alfred11111 Jan 25, 2013 9:52 AM Flag

    Accumulate and hold! Do your own DD!

    Sentiment: Strong Buy

  • Reply to

    $25 Target, Very Bulliish!

    by mireksm Jan 18, 2013 9:20 AM
    alfred11111 alfred11111 Jan 25, 2013 2:24 AM Flag

    Accumulate and hold! Do your own DD!

    Sentiment: Strong Buy

  • alfred11111 alfred11111 Jan 25, 2013 2:22 AM Flag

    Accumulate and hold! Do your own DD!

    Sentiment: Strong Buy

  • alfred11111 by alfred11111 Jan 24, 2013 5:40 PM Flag

    Accumulate and hold! Do your own DD!

    Sentiment: Strong Buy

  • alfred11111 alfred11111 Jan 24, 2013 3:49 PM Flag

    Accumulate and hold! DO your own DD!

    Sentiment: Strong Buy

  • Reply to

    Knut Olstad = Double Digits!, $25 Target!

    by alfred11111 Jan 24, 2013 11:48 AM
    alfred11111 alfred11111 Jan 24, 2013 12:05 PM Flag

    Accumulate and hold!

    Sentiment: Strong Buy

  • Stay with the facts, anyone who follows Biotech knows the potential for a major partnership or buyout of STEM must be taken seriously. Frankly, shareholders of STEM will likely demand significant price appreciations if multi-aggregated offers develop.

    STEM - Stemcells Inc.Facts:

    1) Roger Perlmutter is the former Executive Vice President of Research and Development of Amgen and is on the STEM Board of Directors

    2) STEM Pipeline: NS HuCNS-SC®
    Spinal Cord Injury
    PMD
    Retinal Disorders (AMD)
    Alzheimers
    Stroke

    3) STEM proprietary HuCNS-SC® is the global standard

    4) Liver Program: hLEC™ (human liver engrafting cells)

    5) Manufacturing: HuCNS-SC® (FDA) registered

    6) Cambridge, UK facility offers contract development, scale-up and production services using our automated TAP Biosystems CompacT® SelecT Robotic platform.

    7) Only a few ofSC Proven® Products on the market (there are more):
    Rat Pluripotent Stem Cell Culture Medium
    GS2-M ES & iPS Cell Culture Medium
    iSTEM Embryonic Stem Cell Culture Medium
    NDiff N2 Neuronal Supplement
    NDiff N2-AF Animal Component-free Neuronal Supplement
    NDiff N27 Neuronal Supplement
    NDiff N27-AF Animal Component-free Neuronal Supplement
    NDiff 227 Neural Differentiation Medium
    RHB-A Stem Cell Culture Medium
    RHB-Basal Basal Formulation of RHB-A Cell Culture Medium
    Ultra Primary Human Fibroblasts for Genetic Reprogramming
    Ultra-primary human fibroblast cell line derived from a normal adult male abdominal skin.
    Human Neural CortexStem Cell Kit
    Human Neural Stem Cell (hNSC) line derived from donated brain tissue.
    Human Neural HindbrainStem Cell Kit
    Human Neural Stem Cell (hNSC) line derived from donated brain tissue.
    Human Neural Stem Cell (hNSC) line derived from donated brain tissue.
    Human Neural Stem Cell (hNSC) line derived from donated tissue
    GS1-RRat Pluripotent Stem Cell Culture Medium
    GS2-MES & iPS Cell Culture Medium
    iSTEMEmbryonic Stem Cell Culture Medium
    NDiff N2Neuronal Supplement
    NDiff N2-AFAnimal Component-free Neuronal Supplement
    NDiff N27Neuronal Supplement
    NDiff N27-AFAnimal Component-free Neuronal Supplement
    NDiff 227Neural Differentiation Medium
    RHB-AStem Cell Culture Medium
    STEM24 APC-conjugatedMouse Monoclonal Antibody Specific for Human CD24
    STEM24 UnconjugatedMouse Monoclonal Antibody Specific for Human CD24
    STEM24 UnconjugatedMouse Monoclonal Antibody Specific for Human CD24
    STEM101 Mouse Monoclonal Antibody Specific for Human Ku80 Cell Nucleus Marker
    STEM121 Mouse Monoclonal Antibody Specific for Human Cytoplasmic Marker
    STEM123 Mouse Monoclonal Antibody Specific for Human GFAP
    STEMmES-DPurified Mouse ES Cell gDNA
    STEMmES-RPurified Mouse ES Cell RNA
    STEMmES-PPurified Mouse ES Cell Protein
    STEMmES-TripletKit - 1 each of STEMmES-D, -R, -P
    STEMmENS-DPurified Mouse ES Cell-derived NS Cell gDNA
    STEMmENS-RPurified Mouse ES Cell-derived NS Cell RNA
    STEMmENS-PPurified Mouse ES Cell-derived NS Cell Protein
    STEMmENS-TripletKit - 1 each of STEMmENS-D, -R, -P
    STEMmFNS-DPurified Mouse Fetal Brain-derived NS Cell gDNA
    STEMmFNS-RPurified Mouse Fetal Brain-derived NS Cell RNA
    STEMmFNS-TripletKit - 1 each of STEMmFNS-D, -R, -P

    Sentiment: Strong Buy

  • Reply to

    $25 Target, Very Bulliish!

    by mireksm Jan 18, 2013 9:20 AM
    alfred11111 alfred11111 Jan 24, 2013 11:47 AM Flag

    Accumulate and hold! Do your own DD!

    Sentiment: Strong Buy

  • alfred11111 alfred11111 Jan 24, 2013 2:17 AM Flag

    Accumulate and hold! Do your own DD!

    Sentiment: Strong Buy

  • alfred11111 alfred11111 Jan 24, 2013 2:15 AM Flag

    Accumulate and hold! Do your own research!

    Sentiment: Strong Buy

  • alfred11111 alfred11111 Jan 23, 2013 4:31 PM Flag

    Accumulate and hold! DO your own DD!

    Sentiment: Strong Buy

  • alfred11111 alfred11111 Jan 23, 2013 3:54 PM Flag

    Very Bullish! Do your own research!

    Sentiment: Strong Buy

  • Reply to

    Commercialization, Innovation!!! $25 Target!

    by ddepierdiou Jan 23, 2013 2:05 PM
    alfred11111 alfred11111 Jan 23, 2013 3:53 PM Flag

    Very BULLISH! DO your own DD!

    Sentiment: Strong Buy

  • alfred11111 by alfred11111 Jan 23, 2013 3:52 PM Flag

    Stay with the facts, anyone who follows Biotech knows the potential for a major partnership or buyout of STEM must be taken seriously. Frankly, shareholders of STEM will likely demand significant price appreciations if multi-aggregated offers develop.

    STEM - Stemcells Inc.Facts:

    1) Roger Perlmutter is the former Executive Vice President of Research and Development of Amgen and is on the STEM Board of Directors

    2) STEM Pipeline: NS HuCNS-SC®
    Spinal Cord Injury
    PMD
    Retinal Disorders (AMD)
    Alzheimers
    Stroke

    3) STEM proprietary HuCNS-SC® is the global standard

    4) Liver Program: hLEC™ (human liver engrafting cells)

    5) Manufacturing: HuCNS-SC® (FDA) registered

    6) Cambridge, UK facility offers contract development, scale-up and production services using our automated TAP Biosystems CompacT® SelecT Robotic platform.

    7) Only a few ofSC Proven® Products on the market (there are more):
    Rat Pluripotent Stem Cell Culture Medium
    GS2-M ES & iPS Cell Culture Medium
    iSTEM Embryonic Stem Cell Culture Medium
    NDiff N2 Neuronal Supplement
    NDiff N2-AF Animal Component-free Neuronal Supplement
    NDiff N27 Neuronal Supplement
    NDiff N27-AF Animal Component-free Neuronal Supplement
    NDiff 227 Neural Differentiation Medium
    RHB-A Stem Cell Culture Medium
    RHB-Basal Basal Formulation of RHB-A Cell Culture Medium
    Ultra Primary Human Fibroblasts for Genetic Reprogramming
    Ultra-primary human fibroblast cell line derived from a normal adult male abdominal skin.
    Human Neural CortexStem Cell Kit
    Human Neural Stem Cell (hNSC) line derived from donated brain tissue.
    Human Neural HindbrainStem Cell Kit
    Human Neural Stem Cell (hNSC) line derived from donated brain tissue.
    Human Neural Stem Cell (hNSC) line derived from donated brain tissue.
    Human Neural Stem Cell (hNSC) line derived from donated tissue
    GS1-RRat Pluripotent Stem Cell Culture Medium
    GS2-MES & iPS Cell Culture Medium
    iSTEMEmbryonic Stem Cell Culture Medium
    NDiff N2Neuronal Supplement
    NDiff N2-AFAnimal Component-free Neuronal Supplement
    NDiff N27Neuronal Supplement
    NDiff N27-AFAnimal Component-free Neuronal Supplement
    NDiff 227Neural Differentiation Medium
    RHB-AStem Cell Culture Medium
    STEM24 APC-conjugatedMouse Monoclonal Antibody Specific for Human CD24
    STEM24 UnconjugatedMouse Monoclonal Antibody Specific for Human CD24
    STEM24 UnconjugatedMouse Monoclonal Antibody Specific for Human CD24
    STEM101 Mouse Monoclonal Antibody Specific for Human Ku80 Cell Nucleus Marker
    STEM121 Mouse Monoclonal Antibody Specific for Human Cytoplasmic Marker
    STEM123 Mouse Monoclonal Antibody Specific for Human GFAP
    STEMmES-DPurified Mouse ES Cell gDNA
    STEMmES-RPurified Mouse ES Cell RNA
    STEMmES-PPurified Mouse ES Cell Protein
    STEMmES-TripletKit - 1 each of STEMmES-D, -R, -P
    STEMmENS-DPurified Mouse ES Cell-derived NS Cell gDNA
    STEMmENS-RPurified Mouse ES Cell-derived NS Cell RNA
    STEMmENS-PPurified Mouse ES Cell-derived NS Cell Protein
    STEMmENS-TripletKit - 1 each of STEMmENS-D, -R, -P
    STEMmFNS-DPurified Mouse Fetal Brain-derived NS Cell gDNA
    STEMmFNS-RPurified Mouse Fetal Brain-derived NS Cell RNA
    STEMmFNS-TripletKit - 1 each of STEMmFNS-D, -R, -P

    Sentiment: Strong Buy

  • Stay with the facts, anyone who follows Biotech knows the potential for a major partnership or buyout of STEM must be taken seriously. Frankly, shareholders of STEM will likely demand significant price appreciations if multi-aggregated offers develop.

    STEM - Stemcells Inc.Facts:

    1) Roger Perlmutter is the former Executive Vice President of Research and Development of Amgen and is on the STEM Board of Directors

    2) STEM Pipeline: NS HuCNS-SC®
    Spinal Cord Injury
    PMD
    Retinal Disorders (AMD)
    Alzheimers
    Stroke

    3) STEM proprietary HuCNS-SC® is the global standard

    4) Liver Program: hLEC™ (human liver engrafting cells)

    5) Manufacturing: HuCNS-SC® (FDA) registered

    6) Cambridge, UK facility offers contract development, scale-up and production services using our automated TAP Biosystems CompacT® SelecT Robotic platform.

    7) Only a few ofSC Proven® Products on the market (there are more):
    Rat Pluripotent Stem Cell Culture Medium
    GS2-M ES & iPS Cell Culture Medium
    iSTEM Embryonic Stem Cell Culture Medium
    NDiff N2 Neuronal Supplement
    NDiff N2-AF Animal Component-free Neuronal Supplement
    NDiff N27 Neuronal Supplement
    NDiff N27-AF Animal Component-free Neuronal Supplement
    NDiff 227 Neural Differentiation Medium
    RHB-A Stem Cell Culture Medium
    RHB-Basal Basal Formulation of RHB-A Cell Culture Medium
    Ultra Primary Human Fibroblasts for Genetic Reprogramming
    Ultra-primary human fibroblast cell line derived from a normal adult male abdominal skin.
    Human Neural CortexStem Cell Kit
    Human Neural Stem Cell (hNSC) line derived from donated brain tissue.
    Human Neural HindbrainStem Cell Kit
    Human Neural Stem Cell (hNSC) line derived from donated brain tissue.
    Human Neural Stem Cell (hNSC) line derived from donated brain tissue.
    Human Neural Stem Cell (hNSC) line derived from donated tissue
    GS1-RRat Pluripotent Stem Cell Culture Medium
    GS2-MES & iPS Cell Culture Medium
    iSTEMEmbryonic Stem Cell Culture Medium
    NDiff N2Neuronal Supplement
    NDiff N2-AFAnimal Component-free Neuronal Supplement
    NDiff N27Neuronal Supplement
    NDiff N27-AFAnimal Component-free Neuronal Supplement
    NDiff 227Neural Differentiation Medium
    RHB-AStem Cell Culture Medium
    STEM24 APC-conjugatedMouse Monoclonal Antibody Specific for Human CD24
    STEM24 UnconjugatedMouse Monoclonal Antibody Specific for Human CD24
    STEM24 UnconjugatedMouse Monoclonal Antibody Specific for Human CD24
    STEM101 Mouse Monoclonal Antibody Specific for Human Ku80 Cell Nucleus Marker
    STEM121 Mouse Monoclonal Antibody Specific for Human Cytoplasmic Marker
    STEM123 Mouse Monoclonal Antibody Specific for Human GFAP
    STEMmES-DPurified Mouse ES Cell gDNA
    STEMmES-RPurified Mouse ES Cell RNA
    STEMmES-PPurified Mouse ES Cell Protein
    STEMmES-TripletKit - 1 each of STEMmES-D, -R, -P
    STEMmENS-DPurified Mouse ES Cell-derived NS Cell gDNA
    STEMmENS-RPurified Mouse ES Cell-derived NS Cell RNA
    STEMmENS-PPurified Mouse ES Cell-derived NS Cell Protein
    STEMmENS-TripletKit - 1 each of STEMmENS-D, -R, -P
    STEMmFNS-DPurified Mouse Fetal Brain-derived NS Cell gDNA
    STEMmFNS-RPurified Mouse Fetal Brain-derived NS Cell RNA
    STEMmFNS-TripletKit - 1 each of STEMmFNS-D, -R, -P

    Sentiment: Strong Buy

  • LifeTech Capital

    Home
    About
    Research
    Investment Banking
    Capital Markets
    Investors
    Events
    News
    Contact
    StemCells Inc. (STEM)
    You are here: Home » Covered Companies » StemCells Inc. (STEM) » StemCells (STEM) Update 11-13-12
    13NOV2012
    StemCells (STEM) Update 11-13-12
    Posted in StemCells Inc. (STEM) | Comments Off
    Unprecedented Results Shown in PMD & Spinal Cord
    Dosing Begins in Dry AMD Patients
    Dosing Begins in AIS-B Cohort for Spinal Cord Injury
    Healthy Pro Forma Cash Balance of $27.3M
    Download Full 32-Page Update Report with Important Disclosures: STEM Update 11-13-12
    1.) Unprecedented Results Confirmed as Pelizaeus-Merzbacher Disease (PMD) Phase I Data Published in Journal: On October 10, 2012 StemCells Inc. announced the rare, simultaneous publication of 2 peer-reviewed papers in Science Translational Medicine covering both the successful preclinical animal studies and the successfully completed Phase I human clinical trial using their HuCNS-SC® (purified human neural stem cells) for severe myelination disorders. The animal study demonstrated that implanted HuCNS-SC in neonatal and juvenile mice resulted in new functional myelin, oligodendrocyte stem cell differentiation, improved conductivity. These animal results were then subsequently validated in humans where all 4 patients experienced improvement in myelination relative to changes in the non-transplanted regions in the brain in the Phase I clinical trial. Highlights of the trial were: (see Phase I Human Trial of HuCNS-SC® in Pelizaeus-Merzbacher Disease)
    Progressive and durable donor-cell derived myelination in all 4 patients
    Small but measureable gains in motor and/or cognitive function in 3 of the 4 patients (the 4th patient remained clinically stable)
    After 1 year, MRI showed changes compatible with increased myelination in the region of the transplantation. The MRI signs of myelination persisted even after immunosuppression was stopped at 9 months and in fact, were also found to progress over time.
    The development of new myelin signals is unprecedented in patients with conatal PMD and is consistent with HuCNS-SC engraftment.
    Finally, as in all previous animal and human studies, the HuCNS-SC implantations were safe with no adverse events attributable to the stem cells. Investors should also note that these results may also be applicable to other leukodystrophies, as well as more common myelin disorders including transverse myelitis, multiple sclerosis and periventricular white matter injury seen in cerebral Palsy.
    StemCells Inc. is expected to discuss the proposed Phase II clinical design with the FDA in Q1’13. Due to the ultra-orphan indication of PMD, we believe it may be possible for a controlled Phase II trial with earlier stage patients to provide the basis for accelerated FDA approval.
    2.) Unprecedented Interim Results for Complete Thoracic Spinal Cord Injury: On September 4, 2012, StemCells Inc. announced interim 6-month data from the 1st patient cohort (AIS-A) in the Phase I/II clinical trial of their HuCNS-SC® for thoracic chronic spinal cord injury. The results showed that 2 out of the 3 patients showed considerable gains in sensory function and the third patient remains stable. The trial represents the first time that neural stem cells have been transplanted as a potential therapeutic agent for spinal cord injury. Dr. Armin Curt, Professor and Chairman of the Spinal Cord Injury Center at Balgrist University Hospital, University of Zurich and principal investigator for the clinical trial stated “The gains in sensation have evolved in a progressive pattern below the level of injury and are unanticipated in spinal cord injury patients with this severity of injury, suggesting that the neural stem cells are having a beneficial clinical effect. Sensory function of all these patients was stable before transplantation, so the reappearance of sensation is rather unexpected.” It is believed that this is the first time a significant sensory improvement has been reported in patients with complete spinal cord injury following stem cell transplantation. Highlights of the interim results were: (see Phase I/II Human Trial HuCNS-SC® for Chronic Thoracic Spinal Cord Injury)
    The first cohort consisted of 3 patients classified as AIS-A having complete injury to the thoracic (chest-level) spinal cord. These patients have what is considered to be a “complete” injury, or no movement or feeling below the level of the injury.
    Changes in sensitivity to touch, heat and electrical stimuli were observed in well-defined and consistent areas below the level of injury in 2 of the patients, while no changes were observed in the third patient.
    Importantly, tests of perception of different sensory stimuli as well as measures of electrical impulse transmission across the site of injury correlate with the clinical examination, providing independent and objective confirmation of the changes in sensory function.
    We are anticipating the final 12-month AIS-A patient data in Q1 2013. Finally, on September 27, 2012, StemCells Inc. announced that the 1st patient with an incomplete spinal cord injury (AIS-B cohort) had been enrolled in the Phase I/II clinical trial in chronic thoracic spinal cord injury and transplanted with StemCells Inc.’s HuCNS-SC® neural stem cells. Investors should note that this represents the 1st time neural stem cells have been transplanted into a patient that still has sensory function below the injury.
    3.) Patient Dosing Begins for Dry AMD Phase I/II Trial: On October 4, 2012 StemCells, Inc. announced that the first patient in their Phase I/II trial for Dry Age-Related Macular Degeneration (Dry AMD) has been enrolled and transplanted. The trial is designed to evaluate the safety and preliminary efficacy of HuCNS-SC® (purified human neural stem cells) for Dry AMD. It is designed as an open-label dose-escalating trial in 16 patients treating their worst eye with a single injection into the space beneath the retina and results evaluated over the course of 12 months. Investors should note that 85% of all AMD patients currently have the Dry form and 100% of patients with the more serious Wet form progressed from the initial Dry form. The dry form can also cause vision loss without turning into the wet form. (see HuCNS-SC® for Dry AMD)
    4.) $40M in CIRM Development Awards: The California Institute for Regenerative Medicine (CIRM) has awarded up to $40M in matching loans for preclinical development of StemCells Inc.’s HuCNS-SC in both cervical chronic spinal cord injury (awarded July 26th) and in Alzheimer’s disease (awarded September 6th), with the goal of filing an investigational new drug application (IND) for human clinical trials within 4 years. StemCells Inc. and the CIRM are currently in discussions to work out the details of the awards.
    5.) Significant Cash Balance with Lower Cash Burn: StemCells Inc. had $21.7M in cash as of September 30th plus an additional $5.6M from the exercise of warrants and the sale of shares subsequent to the end of the quarter for a pro forma cash balance of $27.3M. Cash used in Q2 operations was $4.2M and $15M YTD. The company reiterated previous guidance of projected 2012 cash burn of $18M to $20M.
    6.) We are reiterating a Strong Speculative Buy with a Price Target of $4.50 as StemCells Inc. continues to distinguishing themselves as one of the most advanced players in the stem cell space. StemCells Inc.’s HuCNS-SC® (purified human neural stem cells) have shown unprecedented results in human patients for Pelizaeus-Merzbacher Disease (PMD) and for Complete Thoracic Spinal Cord Injury. In Alzheimer’s disease, HuCNS-SC demonstrated the first time human neural stem cells have been shown to have a significant effect on memory in two different animal models. (see Alzheimer’s Disease Background & Development Program) With a Dry AMD trial which recently began dosing, the Spinal Cord Injury trial advancing to AIS-B patients, a potential registration trial for PMD and $40M in CIRM awards, we believe StemCells Inc. management team and science continues to be successfully validated. Our Strong Speculative Buy rating and 12-18 month target price of $4.50 is based on 30x estimated 2016 EPS discounted 55% for cumulative risks in a first-in-class stem cell therapy.
    Download Full 32-Page Update Report with Important Disclosures: STEM Update 11-13-12

    Sentiment: Strong Buy

  • Reply to

    Knut Olstad will take STEM to DOUBLE digits!

    by matyldainmendota Jan 23, 2013 12:53 PM
    alfred11111 alfred11111 Jan 23, 2013 1:43 PM Flag

    Accumulate and hold!

    Sentiment: Strong Buy

  • alfred11111 by alfred11111 Jan 23, 2013 12:59 PM Flag

    Stay with the facts, anyone who follows Biotech knows the potential for a major partnership or buyout of STEM must be taken seriously. Frankly, shareholders of STEM will likely demand significant price appreciations if multi-aggregated offers develop.

    STEM - Stemcells Inc.Facts:

    1) Roger Perlmutter is the former Executive Vice President of Research and Development of Amgen and is on the STEM Board of Directors

    2) STEM Pipeline: NS HuCNS-SC®
    Spinal Cord Injury
    PMD
    Retinal Disorders (AMD)
    Alzheimers
    Stroke

    3) STEM proprietary HuCNS-SC® is the global standard

    4) Liver Program: hLEC™ (human liver engrafting cells)

    5) Manufacturing: HuCNS-SC® (FDA) registered

    6) Cambridge, UK facility offers contract development, scale-up and production services using our automated TAP Biosystems CompacT® SelecT Robotic platform.

    7) Only a few ofSC Proven® Products on the market (there are more):
    Rat Pluripotent Stem Cell Culture Medium
    GS2-M ES & iPS Cell Culture Medium
    iSTEM Embryonic Stem Cell Culture Medium
    NDiff N2 Neuronal Supplement
    NDiff N2-AF Animal Component-free Neuronal Supplement
    NDiff N27 Neuronal Supplement
    NDiff N27-AF Animal Component-free Neuronal Supplement
    NDiff 227 Neural Differentiation Medium
    RHB-A Stem Cell Culture Medium
    RHB-Basal Basal Formulation of RHB-A Cell Culture Medium
    Ultra Primary Human Fibroblasts for Genetic Reprogramming
    Ultra-primary human fibroblast cell line derived from a normal adult male abdominal skin.
    Human Neural CortexStem Cell Kit
    Human Neural Stem Cell (hNSC) line derived from donated brain tissue.
    Human Neural HindbrainStem Cell Kit
    Human Neural Stem Cell (hNSC) line derived from donated brain tissue.
    Human Neural Stem Cell (hNSC) line derived from donated brain tissue.
    Human Neural Stem Cell (hNSC) line derived from donated tissue
    GS1-RRat Pluripotent Stem Cell Culture Medium
    GS2-MES & iPS Cell Culture Medium
    iSTEMEmbryonic Stem Cell Culture Medium
    NDiff N2Neuronal Supplement
    NDiff N2-AFAnimal Component-free Neuronal Supplement
    NDiff N27Neuronal Supplement
    NDiff N27-AFAnimal Component-free Neuronal Supplement
    NDiff 227Neural Differentiation Medium
    RHB-AStem Cell Culture Medium
    STEM24 APC-conjugatedMouse Monoclonal Antibody Specific for Human CD24
    STEM24 UnconjugatedMouse Monoclonal Antibody Specific for Human CD24
    STEM24 UnconjugatedMouse Monoclonal Antibody Specific for Human CD24
    STEM101 Mouse Monoclonal Antibody Specific for Human Ku80 Cell Nucleus Marker
    STEM121 Mouse Monoclonal Antibody Specific for Human Cytoplasmic Marker
    STEM123 Mouse Monoclonal Antibody Specific for Human GFAP
    STEMmES-DPurified Mouse ES Cell gDNA
    STEMmES-RPurified Mouse ES Cell RNA
    STEMmES-PPurified Mouse ES Cell Protein
    STEMmES-TripletKit - 1 each of STEMmES-D, -R, -P
    STEMmENS-DPurified Mouse ES Cell-derived NS Cell gDNA
    STEMmENS-RPurified Mouse ES Cell-derived NS Cell RNA
    STEMmENS-PPurified Mouse ES Cell-derived NS Cell Protein
    STEMmENS-TripletKit - 1 each of STEMmENS-D, -R, -P
    STEMmFNS-DPurified Mouse Fetal Brain-derived NS Cell gDNA
    STEMmFNS-RPurified Mouse Fetal Brain-derived NS Cell RNA
    STEMmFNS-TripletKit - 1 each of STEMmFNS-D, -R, -P

    Sentiment: Strong Buy

  • alfred11111 alfred11111 Jan 23, 2013 10:12 AM Flag

    Accumulate and hold! Do your own DD!

    Sentiment: Strong Buy

ITRI
47.63-0.55(-1.14%)Aug 31 4:00 PMEDT